Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 36

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 36
---
 the recording of goodwill as part of the Merger; (4) the conversion of related -partyloans by Kadimastem into equity; (5) the recording of accruals for transaction -relatedcosts; (6) the elimination of Kadimastem’s share capital and share premium, and NLS’s accumulated deficit in connection with the reverse triangular merger; and (7) the recording of NLS Common Shares issued as part of the Merger to the Kadimastem shareholders, as Kadimastem will be the surviving operating entity for accounting purposes. 21

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Unaudited Pro Forma Condensed Combined Balance Sheets

|                                                                                       |     | As of June 30, 2025 |            |     |               |           |     |             |   |     |       |     |             |             |   |     |       |     |           |            |
|:--------------------------------------------------------------------------------------|:----|:--------------------|-----------:|:----|:--------------|----------:|:----|:------------|:--|:----|:------|:----|:------------|------------:|:--|:----|:------|:----|:----------|-----------:|
|                                                                                       |     | Kadimastem          
 Ltd.                |            |     | NLS           
 Pharmaceutics 
 Ltd. And      
 Subsidiaries  |           |     | Pre-Merger  
 Transaction 
 Accounting  
 Adjustments |   |     | Notes |     | Transaction 
 Accounting  
 Adjustments |             |   |     | Notes |     | Pro Forma 
 Combined  |            |
| ASSETS:                                                                               |     |                     |            |     |               |           |     |             |   |     |       |     |             |             |   |     |       |     |           |            |
| Current assets:                                                                       |     |                     |            |     |               |           |     |             |   |     |       |     |             |             |   |     |       |     |           |            |
| Cash and cash equivalents                                                             |     | $                   |    298,932 |     | $             | 3,072,376 |     | $           | — |     |       |     | $           |   1,952,409 |   |     | -A    |     | $         |